Fierce Pharma
JULY 26, 2024
Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European r | Despite winning approvals in a range of countries like the U.S., China and Japan, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European regulators.
MedCity News
JULY 26, 2024
GenAI will help healthcare reach its destination of efficiency and superior outcomes, but we can’t lose sight of the need for human touch, quality interactions and data to navigate us forward. The post GenAI is a Goal but Not the Destination in Healthcare appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 26, 2024
Amid the sturm und drang over Inflation Reduction Act (IRA) drug price negotiations, Bristol Myers Squibb has been among the biopharma companies casting the most woe over the oncoming measures. | Bristol Myers Squibb CEO Chris Boerner said after seeing the final negotiated price for Eliquis that he is "increasingly confident" the company can navigate the impact of the IRA.
Pharma IQ
JULY 26, 2024
Discover how AI is transforming drug discovery and the future of AI in pharmaceutical research.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JULY 26, 2024
After Eli Lilly’s Olumiant won the distinction of becoming the first med approved by the FDA to treat the follicle-attacking autoimmune disease alopecia areata, Pfizer followed up with a green ligh | The FDA signed off on Sun’s oral JAK inhibitor deuruxolitinib to treat adults with severe alopecia areata. The drug is now approved in 8 mg tablets under the brand name Leqselvi.
MedCity News
JULY 26, 2024
The attack has given detailed dossiers on millions of lives to criminals, employers, enemies and anyone with the means and motivation to exploit them. This isn’t just another data breach, it’s a healthcare catastrophe — and it’s being inexplicably downplayed. The post Credit Monitoring Won’t Save You: The True Fallout of the Change Healthcare Hack is Just Beginning appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JULY 26, 2024
CHMP recommends against approval of Eisai, Biogen's Alzheimer's disease therapy Leqembi, saying side effects outweigh its benefits
Fierce Pharma
JULY 26, 2024
Merely a month into an FDA approval for a broad first-line endometrial cancer population, Merck’s Keytruda has some company. | Merely a month into an FDA approval for a broad first-line endometrial cancer population, Merck’s Keytruda has some company in the form of a matching go-ahead by GSK's Jemperli.
MedCity News
JULY 26, 2024
The EMA’s Committee for Medicinal Products for Human Use expressed concern about brain complications associated with the Eisai Alzheimer’s drug, Leqembi. Eisai said it will ask the committee to reconsider the negative opinion. The post EMA Committee’s Negative Opinion for Eisai Alzheimer’s Drug Focuses on Safety Risks appeared first on MedCity News.
Fierce Pharma
JULY 26, 2024
While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions. | While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JULY 26, 2024
As other industries confront what some see as a ‘wild west’ in terms of AI adoption, the healthcare industry is already using it, with guardrails in place to protect the patients and healthcare workers who are its customers. To maintain this momentum and not stymie it, policies must be in place that spur continued adoption of this technology. The post Without the Right Policies, U.S.
PharmaTimes
JULY 26, 2024
Researchers predicted the onset of 67 diseases, out-performing current standard models
pharmaphorum
JULY 26, 2024
Leading figures from industry and academia, including AstraZeneca, have urged UK PM Keir Starmer to turn the Oxford-Cambridge region into the "crown jewel" of his industrial growth plan
PharmaTimes
JULY 26, 2024
The new Human Gut Microbiome Atlas could help treat conditions including IBS and AMR
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
JULY 26, 2024
Disadvantaged counties are less likely to have Medicare Advantage plans with 4.5 stars or higher and more likely to have plans with 3.5 stars or lower, a new study found. The post Report: Higher-Rated MA Plans Are Less Available in Vulnerable Counties appeared first on MedCity News.
Pharmaceutical Commerce
JULY 26, 2024
The latest news for pharma industry insiders.
pharmaphorum
JULY 26, 2024
Pfizer's haemophilia B gene therapy is approved in EU as Durveqtix, becoming the first alternative to CSL Behring's Hemgenix
Healthcare Success
JULY 26, 2024
The Raleigh House, a valued client and marketing partner, had a clear vision: elevate their website's user experience and project an image of luxury and exclusivity. This, they believed, would resonate with their target audience and boost engagement. While a complete website redesign was on the table, we knew we could achieve some "quick wins" first.
PharmaVoice
JULY 26, 2024
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.
Pharmaceutical Technology
JULY 26, 2024
The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.
pharmaphorum
JULY 26, 2024
Vaccination with GSK's recombinant shingles vaccine Shingrix could delay the onset of dementia, according to researchers in the UK.A study published in Nature Medicine suggests that people administered Shingrix have a lower risk of dementia compared to those given Zostavax - an older shingles shot based on a different technology – and builds on earlier research suggesting a benefit from this type of vaccination.
Pharmaceutical Technology
JULY 26, 2024
Mankind Pharma has announced a definitive agreement for the acquisition of Bharat Serums and Vaccines (BSV) for Rs136.3bn ($1.6bn).
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
JULY 26, 2024
The investigational drug achieved non-inferiority compared to routine Factor VIII.
Nixon Gwilt Law
JULY 26, 2024
Food as Medicine (FaM), also referred to as ‘Food Is Medicine’ or ‘Food Is Health,’ is playing a significant role in the ever-evolving healthcare landscape. Innovative business models in the FaM space include telehealth-enabled dietitian networks, mobile-ordered meal kits, AI-powered meal plan creators, and integrated nutrition pilot programs. The FaM ecosystem includes stakeholders ranging from dietitians and behavioral support providers focused on chronic conditions, to retail grocery stores a
Pharmacy Times
JULY 26, 2024
The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.
Contrarian Sales Techniques
JULY 26, 2024
What's Happening? Maybank is introducing a new rule that will make it harder for scammers to steal your money. Starting July 31, 2024 , there will be a 12-hour waiting period whenever you ask to increase your online transfer limits. Why is Maybank Doing This? Scammers love to quickly increase transfer limits on your account and then steal your money.
Pharmacy Times
JULY 26, 2024
Unbridled drugflation, or a point-in-time measure of the rising cost of pharmacy benefits, is taking its toll on corporate bottom lines and household budgets.
PharmaTech
JULY 26, 2024
The HemoTemp II Blood Bag Temperature Indicator, which is an FDA-approved medical device, and the HemoTemp II Activator both were given the “Standards-Compliant” seal.
Pharmacy Times
JULY 26, 2024
The new approach could optimize precision medicine and lead to better outcomes across a variety of disease states.
Impetus Digital
JULY 26, 2024
Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in rem
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
289 
Let's personalize your content